Clinical Trials Logo

Recurrent or Metastatic clinical trials

View clinical trials related to Recurrent or Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT06413992 Recruiting - Clinical trials for Endometrial Carcinoma

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Start date: May 10, 2024
Phase: Phase 2
Study type: Interventional

This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.

NCT ID: NCT05294172 Active, not recruiting - Clinical trials for Nasopharyngeal Carcinoma

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: June 16, 2022
Phase: Phase 3
Study type: Interventional

The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1

NCT ID: NCT03848286 Completed - Clinical trials for Nasopharyngeal Carcinoma

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: March 6, 2019
Phase: Phase 2
Study type: Interventional

The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1